Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) - Pipeline Review, H2 2016

  • ID: 3846521
  • Drug Pipelines
  • 38 pages
  • Global Markets Direct
1 of 6
Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) - Pipeline Review, H2 2016

Summary

‘Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) - Pipeline Review, H2 2016’, provides in depth analysis on Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) targeted pipeline therapeutics.

The report provides comprehensive information on the Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) targeted therapeutics development and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA)
- The report reviews Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) targeted therapeutics and enlists all their major and minor projects
- The report assesses Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6
List of Tables

List of Figures

Introduction

Report Coverage

Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) Overview

Therapeutics Development

Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) - Products under Development by Stage of Development

Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) - Products under Development by Therapy Area

Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) - Products under Development by Indication

Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) - Products under Development by Companies

Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) - Products under Development by Universities/Institutes

Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Route of Administration

Assessment by Molecule Type

Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) - Companies Involved in Therapeutics Development

Inovio Pharmaceuticals, Inc.

Lipotek Pty Ltd.

Polymun Scientific Immunbiologische Forschung GmbH

Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) - Drug Profiles

HG856-A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HG856-BCG - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HG856-SeV - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RSQ-15 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SSIH-56IC31 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TB/FLU-04L - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tuberculosis vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tuberculosis vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) - Featured News & Press Releases

Nov 08, 2013: Valneva: SSI and Aeras initiate Phase I/IIa Clinical Trial for Tuberculosis Vaccine Candidate Using IC31 Adjuvant

Jan 11, 2012: Intercell And Statens Serum Institut Progress Vaccine Clinical Development To Fight Tuberculosis

Dec 01, 2011: Vaccine Targeting Latent Tuberculosis Enters Clinical Testing

Jan 24, 2011: Researchers At Statens Serum Institut Develop New Vaccine With Dual Protection Against Tuberculosis

Jan 24, 2011: Researchers Develop New Vaccine With Dual Protection Against Tuberculosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Indication, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Number of Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Pipeline by Inovio Pharmaceuticals, Inc., H2 2016

Pipeline by Lipotek Pty Ltd., H2 2016

Pipeline by Polymun Scientific Immunbiologische Forschung GmbH, H2 2016 23List of Figures

Number of Products under Development for, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Type, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6
Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) ESAT-6 is a secretory protein and potent T cell antigen secretory antigen produced by Mycobacterium tuberculosis. It modulates host immune responses.

Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Preclinical and Discovery stages are 5 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively.

Our latest report Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) – Pipeline Review, H2 2016, outlays comprehensive information on the Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Mycobacterium tuberculosis ESAT 6 Protein EsxA (6 kDa Early Secretory Antigenic Target or esxA) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
Inovio Pharmaceuticals, Inc.
Lipotek Pty Ltd.
Polymun Scientific Immunbiologische Forschung GmbH
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll